Evidence map›Paper›PMID 30786093›Full record

ArticleExperimental physiology2019

Cardiac-specific overexpression of caveolin-3 preserves t-tubular I

Cherrie H T Kong, Simon M Bryant, Judy J Watson, David M Roth, Hemal H Patel, Mark B Cannell, Andrew F James, Clive H Orchard

Open access · hybridAbstract read
In one paragraph

Article in Experimental physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Evolution of the cardiac dyad.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Review
  5. Heat Shock Protein 90 as Therapeutic Target for CVDs and Heart Ageing.International journal of molecular sciences · 2022
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Cherrie H T KongSchool of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Simon M BryantSchool of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.ORCID 0000-0002-2483-6203
Judy J WatsonSchool of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
David M RothVA San Diego Healthcare System and Department of Anesthesiology, University of California, San Diego, La Jolla, CA, USA.
Hemal H PatelVA San Diego Healthcare System and Department of Anesthesiology, University of California, San Diego, La Jolla, CA, USA.
Mark B CannellSchool of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Andrew F JamesSchool of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.ORCID 0000-0002-2035-9489
Clive H OrchardSchool of Physiology, Pharmacology & Neuroscience, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.ORCID 0000-0001-7714-5900
University of Bristol · GBUniversity of California San Diego · US

Funding

Vector Production CoreP01HL066941 · NHLBI · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI MIYANOHARA, ATSUSHI · 2001 to 2017
$34.8M
Caveolae, mitochondria, and cardiac protection.R01HL091071 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PATEL, HEMAL H · 2008 to 2019
$3.8M
Caveolae as capacitors for oxygenR21AG052722 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PATEL, HEMAL H · 2017 to 2018
$444k
Modulation of Natriuretic Peptides via Caveolin in Hypertrophy and Heart Failure.I01BX000783 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI ROTH, DAVID M · 2011 to 2019
–
Novel Therapeutics for Diabetic CardiomyopathyI01BX001963 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI PATEL, HEMAL H · 2013 to 2025
–
BLRD VA I01 BX000783BLRD VA I01 BX001963British Heart Foundation RG/12/10/29802Medical Research Council MR/N002903/1NHLBI NIH HHS P01 HL066941NHLBI NIH HHS R01 HL091071NIA NIH HHS R21 AG052722
6 · The paper itself

Abstract

NEW

findingsWhat is the central question of this study? What is the cellular basis of the protection conferred on the heart by overexpression of caveolin-3 (Cav-3 OE) against many of the features of heart failure normally observed in vivo? What is the main finding and its importance? Cav-3 overexpression has little effect in normal ventricular myocytes but reduces cellular hypertrophy and preserves t-tubular I ABSTRACT: Caveolin-3 (Cav-3) is an 18 kDa protein that has been implicated in t-tubule formation and function in cardiac ventricular myocytes. During cardiac hypertrophy and failure, Cav-3 expression decreases, t-tubule structure is disrupted and excitation-contraction coupling (ECC) is impaired. Previous work has suggested that Cav-3 overexpression (OE) is cardio-protective, but the effect of Cav-3 OE on these cellular changes is unknown. We therefore investigated whether Cav-3 OE in mice is protective against the cellular effects of pressure overload induced by 8 weeks' transverse aortic constriction (TAC). Cav-3 OE mice developed cardiac dilatation, decreased stroke volume and ejection fraction, and hypertrophy and pulmonary congestion in response to TAC. These changes were accompanied by cellular hypertrophy, a decrease in t-tubule regularity and density, and impaired local Ca

Indexed as

AnimalsCalcium ChannelsCalcium SignalingCardiomegalyCaveolin 3Constriction, PathologicEchocardiographyHeart FailureHeart VentriclesMaleMiceMyocytes, CardiacPulmonary CirculationSarcoplasmic ReticulumStroke VolumeVasodilationCalcium ChannelsCav3 protein, mouseCaveolin 3caveolin-3excitation-contraction couplingoverexpressionTACt-tubules

Identifiers

PMID30786093
PMCPMC6488395
OpenAlexW2916992938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.